Novel targeted therapies for eosinophil-associated diseases and allergy.
Eosinophil-associated diseases often present with life-threatening manifestations and/or chronic organ damage. Currently available therapeutic options are limited to a few drugs that often have to be prescribed on a lifelong basis to keep eosinophil counts under control. In the past 10 years, treatment options and outcomes in patients with clonal eosinophilic and other eosinophilic disorders have improved substantially. Several new targeted therapies have emerged, addressing different aspects of eosinophil expansion and inflammation. In this review, we discuss available and currently tested agents as well as new strategies and drug targets relevant to both primary and secondary eosinophilic diseases, including allergic disorders.
['Radonjic-Hoesli|Susanne|S|', 'Valent|Peter|P|', 'Klion|Amy D|AD|', 'Wechsler|Michael E|ME|', 'Simon|Hans-Uwe|HU|']
D000818:Animals D018926:Anti-Allergic Agents D055808:Drug Discovery D004802:Eosinophilia D004804:Eosinophils D006801:Humans D006967:Hypersensitivity D058990:Molecular Targeted Therapy D015398:Signal Transduction
asthma biologicals chronic eosinophilic leukemia hypereosinophilic syndrome tyrosine kinase inhibitors